View in EDS HTML Full Text PDF Full Text

Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.

Saved in:
Bibliographic Details
Title: Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.
Authors: Colletta A; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Cooper KM; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Placentino G; Diabetes Clinic, Azienda Sanitaria Locale Verbano Cusio Ossola (ASL VCO), Verbania, Italy., Devuni D; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Colletta C; Hepatology COQ, Madonna del Popolo Hospital, Omegna, Italy.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 May 15; Vol. 16, pp. 1531295. Date of Electronic Publication: 2025 May 15 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40444235
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Colletta+A%22">Colletta A</searchLink>; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.<br /><searchLink fieldCode="AU" term="%22Cooper+KM%22">Cooper KM</searchLink>; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.<br /><searchLink fieldCode="AU" term="%22Placentino+G%22">Placentino G</searchLink>; Diabetes Clinic, Azienda Sanitaria Locale Verbano Cusio Ossola (ASL VCO), Verbania, Italy.<br /><searchLink fieldCode="AU" term="%22Devuni+D%22">Devuni D</searchLink>; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.<br /><searchLink fieldCode="AU" term="%22Colletta+C%22">Colletta C</searchLink>; Hepatology COQ, Madonna del Popolo Hospital, Omegna, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2025 May 15; Vol. 16, pp. 1531295. <i>Date of Electronic Publication: </i>2025 May 15 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40444235
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2025.1531295
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1531295
    Titles:
      – TitleFull: Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Colletta A
      – PersonEntity:
          Name:
            NameFull: Cooper KM
      – PersonEntity:
          Name:
            NameFull: Placentino G
      – PersonEntity:
          Name:
            NameFull: Devuni D
      – PersonEntity:
          Name:
            NameFull: Colletta C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2025 May 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1664-2392
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in endocrinology
              Type: main
ResultId 1